首页> 美国卫生研究院文献>RMD Open >Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

【2h】

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

机译：校正：对于患有活动性银屑病且先前对肿瘤坏死因子抑制剂反应不足或不耐受的患者单独使用伊克珠单抗或将其与常规的合成疾病缓解风湿药（cDMARDs）混合使用时伊克珠单抗是有效的

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 RMD Open
作者

展开▼
作者单位

展开▼
年(卷),期 2019(5),1
年度 2019
页码 e000692corr
总页数 1
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献

1. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-na???ˉve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1 [J] . Mitsumasa Kishimoto, Catherine L Shuler, Alice Gottlieb, RMD Open . 2017,第2期

机译：在患有生物性银屑病关节炎（PsA）的初生患者中，在有或没有常规的改变疾病的抗风湿药（cDMARDs）的情况下，依克珠单抗的疗效和安全性：SPIRIT-P1结果
2. Original article: Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systemati [J] . Ernest Choy, Nick Freemantle, Clare Proudfoot, RMD Open . 2019,第1期

机译：原始文章：sarilumab联合疗法对类风湿性关节炎患者的疗效和安全性评估，这些患者对传统的改变疾病的抗风湿药或肿瘤坏死因子α抑制剂反应不足：系统性
3. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. [J] . Salliot C, Finckh A, Katchamart W, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2011,第2期

机译：生物抗风湿药在类风湿关节炎中对常规疾病缓解性抗风湿药或抗肿瘤坏死因子药物反应不足的患者的间接比较：一项荟萃分析。
4. Original article: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors [O] . Peter Nash, Frank Behrens, Ana-Maria Orbai, 2018

机译：原始文章：对于患有活动性银屑病关节炎且先前对肿瘤坏死因子抑制剂反应不足或不耐受的患者单独使用伊克珠单抗或将其加入常规的可改变疾病综合性的抗风湿药（cDMARDs）中时伊克珠单抗是有效的
5. FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors [O] . LC Coates, P Mease, ME Husni, 2017

机译：Fri0502 Ixekizumab减少了活跃的银屑病关节炎患者的疾病活动，其患有对肿瘤坏死因子抑制剂的反应不足

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

著录项

相似文献

相关主题

期刊订阅